Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab as Consolidation/Maintenance Therapy After ASCT in Multiple Myeloma
NCT03346135Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jan 2020
- Primary completion
- May 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by City of Hope. Started Jan 2020; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03346135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346135.